



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA
DIPARTIMENTO DI MEDICINA SPECIALISTICA
DIAGNOSTICA E SPERIMENTALE

POLICLINICO DI
SANT'ORSOLA



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Ospedaliero - Universitaria di Bologna

Aggressive Lymphoma Workshop

Bologna, Royal Hotel Carlton

May 13-14, 2019

President: **Pier Luigi Zinzani**

Co-President: **Michele Cavo**

Honorary President: **Sante Tura**

Requested Auspices

ALMA MATER STUDIORUM
UNIVERSITÀ DEGLI STUDI DI BOLOGNA


REGIONE EMILIA-ROMAGNA

AZIENDA OSPEDALIERO-UNIVERSITARIA
DI BOLOGNA

AIL ASSOCIAZIONE ITALIANA CONTRO
LE LEUCEMIE - LINFOMI E MIELOMA
SEZIONE DI BOLOGNA

SIE - SOCIETÀ ITALIANA DI EMATOLOGIA

SIES - SOCIETÀ ITALIANA DI EMATOLOGIA
SPERIMENTALE



Faculty

Jeremy S.	Abramson	Boston, USA
Ranjana	Advani	Stanford, USA
Stephen M.	Ansell	Rochester, USA
Lodovico	Balducci	Tampa, USA
Franco	Cavalli	Bellinzona, Switzerland
Bruce D.	Cheson	Washington, USA
Paolo	Corradini	Milan, Italy
Leo I.	Gordon	Chicago, USA
Martin	Hutchings	Copenhagen, Denmark
Wojciech	Jurczak	Kraków, Poland
Issa F.	Khoury	Houston, USA
Won Seog	Kim	Seoul, Korea
John	Kuruville	Toronto, Canada
Maurizio	Martelli	Rome, Italy
Michel	Meignan	Créteil, France
Ari M.	Melnick	New York, USA
Jean-Marie	Michot	Villejuif, France
Sattva S.	Neelapu	Houston, USA
Owen A.	O' Connor	New York, USA
Laura	Pasqualucci	New York, USA
Ruth	Pettengell	London, United Kingdom
Antonio	Pinto	Naples, Italy
Umberto	Ricardi	Turin, Italy
Davide	Rossi	Bellinzona, Switzerland
Simon	Rule	Plymouth, United Kingdom
Elena	Sabattini	Bologna, Italy
Julia	Scarisbrick	Birmingham, United Kingdom
Stephen	Schuster	Philadelphia, USA
David W.	Scott	Vancouver, Canada
Laurie H.	Sehn	Vancouver, Canada
Margaret	Shipp	Boston, USA
Carole	Soussain	Saint-Cloud, France
Michele	Spina	Aviano-PN, Italy
Louis M.	Staudt	Bethesda, USA
Umberto	Vitolo	Turin, Italy
Wyndham H.	Wilson	Bethesda, USA
Thomas E.	Witzig	Rochester, USA
Anas	Younes	New York, USA
Pier Luigi	Zinzani	Bologna, Italy

02.30 pm Welcoming remarks and introduction

SESSION I: Histopathology, biology and...other

Chairman: **E. Sabbatini**

02.50 pm	Histology	E. Sabbatini
03.10 pm	Epigenetic evolution in lymphoma	A.M. Melnick
03.30 pm	Genetic landscape of DLBCL	L. Pasqualucci
03.50 pm	Mechanism-based therapy of DLBCL	L.M. Staudt
04.10 pm	Use of circulating tumor DNA to genotype aggressive lymphomas	D. Rossi

DIFFUSE LARGE B-CELL LYMPHOMA

SESSION II: Precision medicine

Chairmen: **M. Shipp, A. Younes**

04.30 pm	Genomic classification of DLBCL: implications for precision medicine	L.M. Staudt
04.50 pm	Practical considerations for using genome sequencing data for patient selection	D.W. Scott
05.10 pm	Molecular predictors of response	M. Shipp
05.30 pm	Precision medicine in the era of combination therapy: introduction to the MasterLymph protocol	A. Younes

SESSION III: Double hit and double expressor lymphoma

Chairman: **W.H. Wilson**

05.50 pm	The laboratory challenge	D.W. Scott
06.10 pm	The clinical challenge of double hit lymphoma	W.H. Wilson
06.30 pm	The clinical challenge of double expressor lymphoma	B.D. Cheson

SESSION IV: Update on frontline treatments and other

Chairmen: **L.H. Sehn, U. Vitolo**

08.30 am	How to treat early stage DLBCL	L.H. Sehn
08.50 am	Advanced stage: moving beyond R-CHOP? - the addition of ibrutinib - the addition of lenalidomide	A. Younes T.E. Witzig
09.30 am	How to treat elderly patients	L. Balducci
09.50 am	Why doesn't everyone respond? Primary and secondary resistance to signaling pathway	W.H. Wilson

SESSION V: Specific therapeutical approaches in DLBCL and novel diagnostic

Chairman: **S.M. Ansell**

10.10 am	Role of radiotherapy	U. Ricardi
10.25 am	Transplant	I. Khouri
10.40 am	Innovative imaging tools	M. Meignan
10.55 am	Coffee break	

SESSION VI: CAR T-cell

Chairman: **P. Corradini**

11.10 am	Juliet Study	S. Schuster
11.30 am	Transcend Study	J.S. Abramson
11.50 am	ZUMA-1 Study	S.S. Neelapu

SESSION VII: New Drugs in DLBCL (I)Chairmen: **B.D. Cheson, A. Pinto**

12.10 pm	ADCT-402	O.A. O'Connor
12.25 pm	CC-122	J.M. Michot
12.40 pm	Polatuzumab vedotin	L.H. Sehn
12.55 pm	Checkpoint inhibitors	S.M. Ansell
01.10 pm	Pixantrone	R. Pettengell
01.25 pm	Brentuximab vedotin	J.S. Abramson
01.40 pm	Lunch	

SESSION VIII: New drugs in DLBCL (II)Chairmen: **F. Cavalli, M. Spina**

02.45 pm	Umbralisib	O.A. O'Connor
03.00 pm	Copanlisib	W.S. Kim
03.15 pm	MOR208	W. Jurczak
03.30 pm	TAK-659	L.I. Gordon
03.45 pm	Selinexor	J. Kuruvilla
04.00 pm	Biosimilar Rituximab	W. Jurczak
04.15 pm	Hu5F9-G4 and Rituximab	R. Advani
04.30 pm	Bispecific monoclonal antibodies	M. Hutchings

SESSION IX: Other aggressive entities and situationsChairmen: **R. Advani, M. Martelli**

04.45 pm	Cutaneous T-cell lymphoma	J. Scarisbrick
05.00 pm	Burkitt lymphoma	J.S. Abramson
05.15 pm	Primary mediastinal Large B cell lymphoma	P.L. Zinzani
05.30 pm	Mantle cell lymphoma	S. Rule
05.45 pm	Peripheral T-cell lymphoma	R. Advani
06.00 pm	NK/T-cell lymphoma	W.S. Kim
06.15 pm	Primary CNS	C. Soussain
06.30 pm	Conclusions and arrivederci	

MEETING VENUE

Royal Hotel Carlton

Via Montebello, 8 - 40121 Bologna, Italy

Phone +39 051 249361 - Fax +39 051 249724

www.royalhotelcarltonbologna.com

OFFICIAL LANGUAGE

English

REGISTRATION FEE

Euro 250,00 (Italian VAT included)

The registration fee includes: conference kit, participation in the scientific sessions, attendance certificate, coffee break, lunch, slides of the meeting.

BADGE

All registered participants, speakers and sponsors will be given a badge which they must wear to be admitted to the scientific sessions.

CERTIFICATE OF ATTENDANCE

A certificate will be given to all participants at the end of the meeting.

ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-246084.
- No. 8,4 CME credits for Physicians (disciplines: Hematology, Oncology, Radiotherapy, Pathological Anatomy, Clinical Pathology) and Biologists.
- Educational objective: "linee guida-protocolli-procedure".

EUROPEAN CME CREDITS

The program of the "Aggressive Lymphoma Workshop" has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 12 CME credits for Physicians and Biologists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for credits.

Attendees can create an EBAH-CME account registering on the website: <http://ebah.org> even on site.

CHANGES

Parts of the program may be changed without notice.

Scientific Secretariat

Pier Luigi Zinzani
Istituto di Ematologia
"Lorenzo e Ariosto Seràgnoli"
Via Massarenti, 9 - 40138 Bologna, Italy
Phone +39 051 2143680
Fax +39 051 2144037
E-mail: pierluigi.zinzani@unibo.it

Organizing Secretariat

Studio E.R. Congressi
Via Marconi, 36 - 40122 Bologna, Italy
Phone +39 051 4210559
Fax +39 051 4210174
E-mail: ercongressi@ercongressi.it
www.ercongressi.it